TMOS34 Stock Overview
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Thermo Fisher Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$73.80 |
| 52 Week High | US$75.93 |
| 52 Week Low | US$52.88 |
| Beta | 0.77 |
| 1 Month Change | 10.40% |
| 3 Month Change | 8.47% |
| 1 Year Change | 31.81% |
| 3 Year Change | 12.62% |
| 5 Year Change | 148.28% |
| Change since IPO | 582.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| TMOS34 | BR Life Sciences | BR Market | |
|---|---|---|---|
| 7D | 4.3% | 0% | 0% |
| 1Y | 31.8% | 0% | 0% |
Return vs Industry: TMOS34 exceeded the BR Life Sciences industry which returned 0.6% over the past year.
Return vs Market: TMOS34 exceeded the BR Market which returned -8.7% over the past year.
Price Volatility
| TMOS34 volatility | |
|---|---|
| TMOS34 Average Weekly Movement | 4.6% |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BR Market | 0% |
| 10% least volatile stocks in BR Market | 0% |
Stable Share Price: TMOS34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: TMOS34's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 122,000 | Marc Casper | www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Thermo Fisher Scientific Inc. Fundamentals Summary
| TMOS34 fundamental statistics | |
|---|---|
| Market cap | R$1.28t |
| Earnings (TTM) | R$37.25b |
| Revenue (TTM) | R$252.10b |
36.6x
P/E Ratio5.4x
P/S RatioIs TMOS34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMOS34 income statement (TTM) | |
|---|---|
| Revenue | US$42.88b |
| Cost of Revenue | US$24.82b |
| Gross Profit | US$18.06b |
| Other Expenses | US$11.73b |
| Earnings | US$6.34b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.56 |
| Gross Margin | 42.12% |
| Net Profit Margin | 14.77% |
| Debt/Equity Ratio | 63.0% |
How did TMOS34 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield9%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 00:27 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Thermo Fisher Scientific Inc. is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |